Largest dataset of thousands of proteins marks landmark step for research into human health

This was covered by both national and specialist media, including The Times, PA Media, PharmaPhorum, Technology Networks and Medscape UK. 

First-of-its-kind dataset – based on samples from over 54,000 UK Biobank volunteer participants – lays the foundation for future discovery of new drug targets. 

Today, the scientific journal Nature¹ published the results of the world’s largest and most comprehensive study on the effects of common genetic variation on proteins circulating in the blood and how these associations can contribute to disease. This unprecedented population-scale investigation of proteins, powered by turning biological samples into data from UK Biobank, will help scientists better understand how and why diseases develop, which could help drive the development of new diagnostics and treatments for a wide range of health conditions.

To develop this unique and unparalleled dataset, researchers measured the abundance of nearly 3,000 circulating proteins, many of which were previously difficult to capture, from over 54,000 participants in the UK Biobank – which has been collecting data and tracking the health of 500,000 volunteer participants enrolled between 2006 and 2010. The study identified over 14,000 associations between common genetic variants and proteins circulating in the blood, over 80% of which were previously unknown. Scientists worldwide will be able to access the proteomic data in the coming weeks via UK Biobank².

This landmark study was commissioned, funded, and carried out by the Pharma Proteomics Project, a collaboration between 13 leading biopharmaceutical companies³. The team carried out analyses on the data, demonstrating the vast potential for future research using the study. These include:

• Genome-wide association studies to build an open access library of all the common gene variants that influence protein levels in blood. This can be used to study complex biological processes, such as the immune system, find proteins that are key players in causing disease, identify new drug targets and potentially shorten development time for earlier-stage drug candidates and increase success rates for clinical trials.
• Profiling of blood protein levels across the top 20 most common health conditions in UK Biobank⁴. This revealed that, for example, inflammatory proteins, long thought to contribute towards mental health conditions, are significantly higher in patients with depression.
• Training machine learning models to determine how successfully blood proteins can predict demographic factors. This analysis found that blood proteins can predict age, sex and body mass index (BMI) with very high accuracy. In the future, this technology could be used to compare chronological age with biological age and determine how this is related to risk of future diseases.

"This momentous study offers whole new avenues of research to the biomedical community, and is a leading example of how cross-sector collaboration can bring about results that are so much greater than the sum of their parts. All of these data will soon be available to bona fide researchers across the globe, alongside the existing genomic, lifestyle and health data that UK Biobank holds for its 500,000 volunteers. I am excited for researchers to use these data to identify patterns that could transform our understanding of how diseases develop, and to identify potential new treatment pathways."

Professor Naomi Allen, Chief Scientist of UK Biobank

"To date, the scientific community has invested substantially in genomics for the advancement of precision medicine. However, to identify the right drug for the right patient at the right time, we must move beyond genomics alone. This dataset will help paint a much more nuanced and detailed picture of how the human genome and proteins circulating in the blood influence human health and disease – enabling biomedical researchers to identify new biological associations, find new drug targets and build blood-based diagnostics."

Dr Chris Whelan, Director, Neuroscience, Data Science & Digital Health, Janssen Research & Development, LLC, a Johnson & Johnson Company, Pharma Proteomics Project Lead

Other future innovative work expected to result from this study includes using proteins circulating in the blood to predict whether someone will develop a disease several years before the condition occurs, classifying diseases into distinct biological subtypes, and using proteins in the blood to predict drug efficacy and safety prior to clinical trials.

References

1. Plasma proteomic associations with genetics and health in the UK Biobank, Sun & Whelan et al, Nature, October 2023. https://www.nature.com/articles/s41586-023-06592-6
2. Data will be made available to approved researchers through UK Biobank. Researchers can register to apply from around the world. For more information visit: https://www.ukbiobank.ac.uk/enable-your-research
3. Biopharmaceutical companies in the Pharma Proteomics Project: Alnylam, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Calico, Genentech, a member of the Roche Group, GSK, The Janssen Pharmaceutical Companies of Johnson & Johnson, Novo Nordisk, Pfizer, Regeneron and Takeda.
4. The 20 most prevalent health conditions in UK Biobank:

• Disorders of lipoprotein metabolism and other lipidaemias
• Depression
• Essential (primary) hypertension
• Chronic ischemic heart disease
• Acute upper respiratory infections
• Unspecified acute lower respiratory infection
• Vasomotor and allergic rhinitis
• Asthma
• Gastro-oesophageal reflux disease
• Gastritis and duodenitis
• Diaphragmatic hernia
• Diverticular disease of intestine
• Other diseases of anus and rectum
• Other dermatitis
• Other disorders of skin and subcutaneous tissue
• Other arthrosis
• Other joint disorders
• Dorsalgia
• Other soft tissue disorders
• Other disorders of urinary system